Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy.
Batisse
D
D
Karmochkine
M
M
Si Mohamed
A
A
Piketty
C
C
Kazatchkine
M D
MD
Belec
L
L
D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003062:Codon; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D015751:Genes, pol; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D009154:Mutation; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D018119:Stavudine / Q000627:therapeutic use*; D016896:Treatment Outcome; D017735:Virus Latency; D015215:Zidovudine / Q000494:pharmacology*
D019380:Anti-HIV Agents; D003062:Codon; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D018119:Stavudine